CBL-B Inhibitor Combination to Overcome Suppressive Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer are suboptimal due to low inflammation, lack of co-stimulation signals, and high immune suppressive environments, which can be addressed by inhibiting CBL-B to enhance immune-mediated tumor growth control.
Innovation Solution
Administering a therapeutically effective amount of a CBL-B inhibitor in combination with an anti-PD1/anti-PD-L1 agent to modulate T-cell receptor activation and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used, then cancer treatment is provided, but the response is suboptimal due to low inflammation, no/low co-stimulation signal or high immune suppressive environment
Solution Approach 1:
The patent converts the harmful immune suppressive environment into a beneficial condition by using CBL-B inhibition to transform suppressed T cells into activated effector T cells, thereby converting the harmful suppression into beneficial anti-tumor immunity
Solution Approach 2:
The patent changes the activation threshold parameter of T cells by inhibiting CBL-B, lowering it from a high state (in suppressive environments) to a low state, enabling T cell activation even without co-stimulatory signals or in the presence of immune suppression
2Productivity
If CBL-B inhibition is used to lower T cell activation threshold, then immune-mediated tumor growth control is enhanced, but combination with anti-PD1/anti-PD-L1 is required for optimal effect
Solution Approach 1:
The patent merges two distinct therapeutic mechanisms: CBL-B inhibition (lowering activation threshold) and anti-PD1/anti-PD-L1 therapy (blocking checkpoint inhibition), creating a synergistic combination that overcomes multiple barriers to effective immunotherapy simultaneously
Data Source
AI summary
The present disclosure relates to treatment of a subject in need thereof of comprising administering a therapeutically effective amount of a CBL-B inhibitor and a therapeutically effective amount of an anti PD-1/anti-PD-L1 agent.